ZyVersa Therapeutics, Inc. announced that the European Patent Office has issued a "Notice of Intention to Grant" ZyVersa's patent application covering the company's Phase 2a-ready Cholesterol Efflux Mediator™? VAR 200 (2-hydroxypropyl-beta-cyclodextrin) for use in diabetic nephropathy/diabetic kidney disease. Cholesterol Efflux Mediator™ VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPßCD) is a phase 2a-ready drug in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system, leading to kidney disease progression.

VAR 200 passively and actively removes excess lipids from the kidney. Preclinical studies with VAR 200 in animal models of FSGS, Alport syndrome, and diabetic kidney disease demonstrate that removal of excess cholesterol and lipids from kidney podocytes protects against structural damage and reduces excretion of protein in the urine (proteinuria). The lead indication for VAR 200 is orphan kidney disease focal segmental glomerulosclerosis (FSGS).

VAR 200 has potential to treat other glomerular diseases, including orphan Alport syndrome and diabetic kidney disease.